The Sudoriferous (Sweat) Gland Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Sudoriferous (Sweat) Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sudoriferous (Sweat) Gland Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sudoriferous (Sweat) Gland Disorders and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Sudoriferous (Sweat) Gland Disorders by 12 companies/universities/institutes. The top development phase for Sudoriferous (Sweat) Gland Disorders is phase i with four drugs in that stage. The Sudoriferous (Sweat) Gland Disorders pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Sudoriferous (Sweat) Gland Disorders pipeline products market are: Aquavit Pharmaceuticals, AbbVie and Staidson (Beijing) Biopharmaceuticals.
The key targets in the Sudoriferous (Sweat) Gland Disorders pipeline products market include Synaptosomal Associated Protein 25, Cholinergic Receptor Muscarinic, and Muscarinic Acetylcholine Receptor M3.
The key mechanisms of action in the Sudoriferous (Sweat) Gland Disorders pipeline product include Synaptosomal Associated Protein 25 Inhibitor with four drugs in Phase III. The Sudoriferous (Sweat) Gland Disorders pipeline products include seven routes of administration with the top ROA being Topical and five key molecule types in the Sudoriferous (Sweat) Gland Disorders pipeline products market including Small Molecule, and Protein.
Sudoriferous (Sweat) Gland Disorders overview
Sweat glands, also known as sudoriferous or sudoriparous glands, are small tubular structures of the skin that produce sweat. Sweat glands are a type of exocrine gland, which are glands that produce and secrete substances onto an epithelial surface by way of a duct. It is a skin disease caused by the blockage or inflammation of eccrine sweat glands
For a complete picture of Sudoriferous (Sweat) Gland Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
